Company / Working Capital
Protalix BioTherapeutics, Inc. Working Capital History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$40.2M
FY2025
5-year range
$12.5M / $40.2M
FY2021-FY2025
Trend
+16.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has increased for 3 consecutive years, from $12M in FY2022 to $40M in FY2025.
Based on SEC 10-K filings.
$40M in FY2025 with a 10-year CAGR of -6.0%.
Improved from $24M to $40M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +47.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -6.0%
Key checks
Key Insights
- Protalix BioTherapeutics, Inc.'s working capital has grown for 3 consecutive years.
- 3-year CAGR of +47.7%, indicating consistent growth.
- In FY2025, working capital increased 16.5% year-over-year.
- Peak working capital was recorded in FY2015.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.2M | +16.5% |
| FY2024 | $34.5M | +41.2% |
| FY2023 | $24.4M | +96.0% |
| FY2022 | $12.5M | -56.3% |
| FY2021 | $28.5M | +192.6% |
| FY2020 | -$30.8M | -299.6% |
| FY2019 | -$7.7M | -119.3% |
| FY2017 | $39.9M | +605.6% |
| FY2016 | $5.7M | -92.4% |
| FY2015 | $74.6M | +89.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026